ADBiotech Co., Ltd. (KOSDAQ:179530)
South Korea · Delayed Price · Currency is KRW 3,100.00
+585.00 (23.26%)
At close: Apr 3, 2026
ADBiotech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 12,897 | 11,136 | 10,472 | 10,632 | 11,840 |
Other Revenue | - | - | -0 | -0 | -0 |
| 12,897 | 11,136 | 10,472 | 10,632 | 11,840 | |
Revenue Growth (YoY) | 15.81% | 6.34% | -1.50% | -10.21% | 20.63% |
Cost of Revenue | 7,749 | 7,130 | 7,254 | 7,520 | 6,831 |
Gross Profit | 5,148 | 4,007 | 3,218 | 3,111 | 5,009 |
Selling, General & Admin | 6,607 | 5,833 | 6,239 | 6,284 | 5,333 |
Research & Development | 1,802 | 1,632 | 1,486 | 1,111 | 550.16 |
Amortization of Goodwill & Intangibles | 67.96 | 131.03 | 272.93 | 2.71 | 6.83 |
Other Operating Expenses | 128.8 | 142.67 | 147.27 | 126.59 | 119.71 |
Operating Expenses | 8,649 | 8,124 | 7,990 | 8,095 | 6,564 |
Operating Income | -3,501 | -4,117 | -4,772 | -4,984 | -1,555 |
Interest Expense | -1,816 | -682.06 | -426.4 | -124.68 | -130.23 |
Interest & Investment Income | 87.46 | 76.48 | 149.67 | 6,019 | 5.73 |
Currency Exchange Gain (Loss) | 3.28 | 150.94 | -38.62 | -39.66 | 64.42 |
Other Non Operating Income (Expenses) | 3,871 | 248.95 | -813.25 | 1,435 | -777.68 |
EBT Excluding Unusual Items | -1,355 | -4,323 | -5,901 | 2,306 | -2,392 |
Gain (Loss) on Sale of Investments | -650.25 | -4,263 | 3,023 | 390.47 | -24.16 |
Gain (Loss) on Sale of Assets | - | -4.43 | - | - | 1.82 |
Asset Writedown | -1,503 | -421.96 | -2,580 | - | - |
Pretax Income | -3,508 | -9,013 | -5,457 | 2,696 | -2,415 |
Income Tax Expense | -179.61 | -25.72 | -25.58 | - | 249.77 |
Earnings From Continuing Operations | -3,329 | -8,987 | -5,432 | 2,696 | -2,664 |
Minority Interest in Earnings | 24.57 | 1,035 | 2,568 | - | - |
Net Income | -3,304 | -7,952 | -2,863 | 2,696 | -2,664 |
Net Income to Common | -3,304 | -7,952 | -2,863 | 2,696 | -2,664 |
Shares Outstanding (Basic) | 12 | 9 | 9 | 9 | 8 |
Shares Outstanding (Diluted) | 12 | 9 | 9 | 10 | 8 |
Shares Change (YoY) | 31.45% | -0.00% | -9.33% | 31.17% | 53.77% |
EPS (Basic) | -275.00 | -870.00 | -313.27 | 297.39 | -346.68 |
EPS (Diluted) | -275.00 | -870.00 | -313.27 | 118.54 | -347.00 |
Free Cash Flow | -17,130 | -4,285 | 75.03 | -9,319 | -5,747 |
Free Cash Flow Per Share | -1425.77 | -468.82 | 8.21 | -924.41 | -747.71 |
Gross Margin | 39.91% | 35.98% | 30.73% | 29.26% | 42.31% |
Operating Margin | -27.15% | -36.97% | -45.57% | -46.88% | -13.13% |
Profit Margin | -25.62% | -71.41% | -27.34% | 25.36% | -22.50% |
Free Cash Flow Margin | -132.82% | -38.48% | 0.72% | -87.66% | -48.54% |
EBITDA | -2,544 | -3,092 | -3,639 | -4,258 | -903 |
EBITDA Margin | -19.72% | -27.77% | -34.75% | -40.05% | -7.63% |
D&A For EBITDA | 957.02 | 1,025 | 1,134 | 725.66 | 651.6 |
EBIT | -3,501 | -4,117 | -4,772 | -4,984 | -1,555 |
EBIT Margin | -27.15% | -36.97% | -45.57% | -46.88% | -13.13% |
Advertising Expenses | 488.35 | 76.26 | 1.06 | 344.51 | 271.87 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.